<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978385/" ref="ordinalpos=2864&amp;ncbi_uid=6006524&amp;link_uid=PMC3978385" image-link="/pmc/articles/PMC3978385/figure/F3/" class="imagepopup">Figure 3. Raf isoform switching in NRAS mutant melanoma.  From: NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. </a></div><br /><div class="p4l_captionBody"><b>A.</b> In normal melanocytes, cyclic AMP pathway activation promotes PKA-mediated inhibition of CRAF. Therefore MAPK signaling proceeds through BRAF rather than CRAF in these cells (left panel). <b>B.</b> In NRAS mutant melanoma, inhibition of PKA signaling due to enzymatic activity of phosphodiesterase (PDE) and negative feedback inhibition of BRAF due to activation of the MAPK pathway promotes CRAF-mediated MAPK signaling instead (right panel).</div></div>